News & Events
April 12, 2021
C-Path’s Alzheimer’s Disease Consortium Expands Data Repository
TUCSON, Ariz., April 12, 2021 — The Critical Path Institute’s (C-Path) Critical Path for Alzheimer’s Disease (CPAD) Consortium today announced that it is significantly expanding its Alzheimer’s disease (AD) patient-level data repository with high-quality contemporary industry clinical trial datasets, focusing on early stages of the disease.
November 17, 2020
Alzheimer’s Disease Data Initiative Launches, Critical Path for Alzheimer’s Disease Consortium to Partner
TUCSON, Ariz., November 17, 2020 — The Critical Path Institute’s (C-Path) Critical Path for Alzheimer’s Disease (CPAD) Consortium today announced its participation as a Partner with the Alzheimer’s Disease Data Initiative (ADDI), a 501(c)(3) medical research organization which launched today. ADDI is dedicated to advancing scientific breakthroughs in the treatment of Alzheimer’s disease (AD) and related dementias.
March 18, 2020
C-Path and Lundbeck Announce a Data Sharing Collaboration to Enable Development of Advanced Drug Development Tools in Alzheimer’s Disease
C-Path and H. Lundbeck A/S are proud to announce that they will work together to significantly improve the scientific community’s insight in Alzheimer’s disease through Lundbeck’s contribution of a unique set of clinical trial data from more than 2,500 AD patients to the Critical Path for Alzheimer’s Disease consortium’s integrated database for qualified researchers across the globe to access.
March 12, 2020
C-Path Selects Experienced Neuroscientist to Lead Alzheimer’s Consortium
The Critical Path Institute (C-Path) today announced it has named Sudhir Sivakumaran, Ph.D., as Executive Director of its Critical Path for Alzheimer’s Disease (CPAD) consortium effective immediately. Dr. Sivakumaran, a neuroscientist and research and development professional, has nearly 20 years combined experience in academic, pre-clinical and early clinical research and development, phase 1 and phase 2 clinical study design, data analysis and diligence and business development. He has been with C-Path since July 2019 as Associate Director for CPAD.
November 5, 2018
Critical Path Institute Rebrands One of Its First Consortia to Highlight Focus on Alzheimer’s DiseaseCritical Path for Alzheimer’s Disease (CPAD) consortium’s refined, refocused mission centers on accelerating therapy development for AD and related forms of dementia TUCSON, Ariz., November 5, 2018 — The Critical Path Institute (C-Path) is pleased to announce that its Critical Path for Alzheimer’s Disease (CPAD) consortium has refined and refocused its mission in celebration of......